As the first collision industry information provider to sign a data licensing agreement with Rivian, Mitchell is proud to be a Platinum Sponsor of the 2024 Certified Collision Network Summit. The Mitchell team will be on-hand to demonstrate how repair shops can leverage Mitchell’s cloud-based estimating and Mitchell Cloud Estimating TruckMax to access OEM repair information for Rivian vehicles. With an abundance of presentations and networking opportunities, this event will help attendees enhance their knowledge of Rivian vehicles and the tools and technology used to repair them.
More stories
FDA Authorizes Second Coronavirus (SARS-CoV2) Vaccine for Use
December 23, 2020
The vaccine produced by Moderna has been granted emergency use authorization for distribution in the United States.
Mitchell Predicts 2021 Trends in Its Fourth Quarter 2020 Industry Trends Report
December 17, 2020
According to Mitchell experts, 2021 will see growth in personal vehicle ownership and electric vehicles, rising accident severity and increasing automation and digitization in the claims process.
GM and Mitchell Launch GM Collision Repair Network in Canada
December 10, 2020
New program focuses on increasing brand loyalty and customer confidence by promoting the proper, safe repair of Chevrolet, Buick, GMC and Cadillac vehicles.
Episode 1: Re-Imagining What's Possible in a Pandemic
December 7, 2020
Ryan and Tony Cotto, director of auto and underwriting policy at National Association of Mutual Insurance Companies (NAMIC), discuss the impact of COVID-19 on automotive insurers. Learn how carriers have quickly adapted to a new normal and how they’re re-imagining the future of claims post-pandemic.
FDA Authorizes Use of First at Home COVID-19 Test Kit
December 2, 2020
The test takes about 30 minutes and an indicator light will note a positive or negative result.
Bamlanivimab Granted Emergency Use Authorization For Early COVID-19 Treatment
November 11, 2020
Bamlanivimab is an investigational monoclonal antibody treatment that has shown promise in treating mild-to-moderate COVID-19 infections.